Hvis der ses et klinisk signifikant fald i hæmoglobin eller hæmatokrit, og andre årsager er udelukket, skal det overvejes at reducere dosis eller afbryde behandlingen.
If a clinically significant decrease in haemoglobin or haematocrit is observed, and other causes have been excluded, dose reduction or discontinuation of treatment should be considered.